Skip to main content
. 2016 Dec 20;22:918–926. doi: 10.2119/molmed.2015.00206

Figure 3.

Figure 3.

Prophylactic inhibition of TNF using ETA in antibody transfer–induced EBA and BP model reduced disease severity. (A–E) Representative clinical pictures on d 12 after injection of mice with rabbit anti-mCOL7C IgG and treatment with (A,B) isotype control (shared with Figure 2) and (C,D) ETA every other day until d 10 starting 2 d prior to the initial anti-mCOL7C IgG injection. Both groups developed erythema and erosions. (E) Clinical disease score, shown as the percentage of body surface area affected by blistering, was reduced in ETA-treated mice (n = 6) compared to isotype-treated mice with EBA (n = 8) at d 8 and d 12. (F) Representative pictures of mouse ears on d 2 after injection with rabbit anti-mCOL17 IgG and treatment with PBS or ETA every other day starting 2 d prior to anti-mCOL17 IgG injection. (E) Clinical disease score, shown as the percentage of ear surface area affected by blistering, was reduced in ETA-treated mice (n = 6) compared to isotype-treated mice with EBA (n = 8) at d 2 (*p < 0.05, **p < 0.01).